Literature DB >> 16463428

Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis.

Carlos Gonzalez-Juanatey1, Javier Llorca, Carlos Garcia-Porrua, Javier Martin, Miguel A Gonzalez-Gay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16463428     DOI： 10.1002/art.21707

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  30 in total

1.  [Biologics and cardiovascular risk].

Authors:  I H Tarner; U Müller-Ladner; C Hamm
Journal:  Z Rheumatol       Date:  2010-10       Impact factor: 1.372

Review 2.  New insights into the functional role of the rheumatoid arthritis shared epitope.

Authors:  Denise E de Almeida; Song Ling; Joseph Holoshitz
Journal:  FEBS Lett       Date:  2011-03-22       Impact factor: 4.124

Review 3.  What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.

Authors:  W G Dixon; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2007-01-24       Impact factor: 19.103

4.  Lack of association between TLR4 rs4986790 polymorphism and risk of cardiovascular disease in patients with rheumatoid arthritis.

Authors:  Mercedes García-Bermúdez; Raquel López-Mejías; Carlos González-Juanatey; Santos Castañeda; José A Miranda-Filloy; Ricardo Blanco; Benjamín Fernández-Gutiérrez; Alejandro Balsa; Isidoro González-Alvaro; Carmen Gómez-Vaquero; Javier Llorca; Javier Martín; Miguel A González-Gay
Journal:  DNA Cell Biol       Date:  2012-02-23       Impact factor: 3.311

5.  Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study.

Authors:  Kristin Angel; Sella A Provan; Magne K Fagerhol; Petter Mowinckel; Tore K Kvien; Dan Atar
Journal:  Am J Hypertens       Date:  2012-03-01       Impact factor: 2.689

6.  Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis.

Authors:  Inmaculada del Rincón; Joseph F Polak; Daniel H O'Leary; Daniel F Battafarano; John M Erikson; Jose F Restrepo; Emily Molina; Agustín Escalante
Journal:  Ann Rheum Dis       Date:  2014-05-20       Impact factor: 19.103

Review 7.  Cardiovascular risk and the use of biologic agents in rheumatoid arthritis.

Authors:  Debbie T Lim; Amy C Cannella; Kaleb D Michaud; Ted R Mikuls
Journal:  Curr Rheumatol Rep       Date:  2014-11       Impact factor: 4.592

Review 8.  Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.

Authors:  Chary López-Pedrera; Maria Ángeles Aguirre; Nuria Barbarroja; Maria José Cuadrado
Journal:  J Biomed Biotechnol       Date:  2010-09-26

9.  Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima-media thickness in female patients with active rheumatoid arthritis.

Authors:  A Ferrante; A R Giardina; F Ciccia; G Parrinello; G Licata; G Avellone; E Giardina; R Impastato; Giovanni Triolo
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

10.  Infliximab improves vascular stiffness in patients with rheumatoid arthritis.

Authors:  M Wong; S P Oakley; L Young; B Y Jiang; A Wierzbicki; G Panayi; P Chowienczyk; B Kirkham
Journal:  Ann Rheum Dis       Date:  2008-10-17       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.